Multiple Myeloma – Talk Bio

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

3 days ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

Pfizer-backed CellCentric Secures $120M for Myeloma Drug Trials

3 weeks ago talkbio0Tagged Accelerated, Approved, CellCentric, Clinical Trials, Inobrodib, Multiple Myeloma, oral drug, p300/CBP inhibitor, Pfizer, Series C

CellCentric; Pfizer; multiple myeloma; Series C funding; inobrodib; p300/CBP inhibitor; oral drug; clinical trials; phase 2/3; accelerated approval

Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer

1 month ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, J&J, Lynozyfic, Multiple Myeloma, Neoplasms, Pfizer, Regeneron

Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology

UK approval brings GSK’s Blenrep back from the brink

2 months ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Blenrep, Cessation of life, dexamethasone, DREAMM-8, Multiple Myeloma, Risk, UK

UK, Approved, Multiple Myeloma, DREAMM-8, dexamethasone, Blenrep, Antibody-Drug Conjugates, Risk, Cessation of life

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

3 months ago talkbio0Tagged Carvykti, competition, Facility (object), Investments, J&J, Johnson and Johnson, Multiple Myeloma, production

Carvykti, Johnson and Johnson, Investments, J&J, Facility (object), Multiple Myeloma, production, competition

Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue

5 months ago talkbio0Tagged Darzalex, Johnson and Johnson, Mental Depression, Multiple Myeloma, Pharmaceutical Sales, Revenue Milestones, Spravato

Johnson & Johnson, Darzalex, Spravato, Pharmaceutical Sales, Multiple Myeloma, Depression Treatment, Revenue Milestones

AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

5 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, GPRC5D, GPRC5D gene, Multiple Myeloma, Simcere, T-Lymphocyte, Trispecific Antibody, Zaiming

AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3

GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment

7 months ago talkbio0Tagged belantamab, Blenrep, Darzalex, DREAMM-7, DREAMM-8, mafodotin, Multiple Myeloma, regulatory, SmithKline Beecham, Survival

GSK, Blenrep, Belantamab mafodotin, Multiple myeloma, DREAMM-7, DREAMM-8, Darzalex, Survival advantage, Regulatory challenges

Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti

7 months ago talkbio0Tagged 2024, Arcellx, Asymmetric Septal Hypertrophy, CAR-T, Carvykti, Effectiveness, Gilead, Multiple Myeloma, relapsed/refractory multiple myeloma, safety profile

Gilead, Arcellx, CAR-T therapy, multiple myeloma, anito-cel, Carvykti, ASH 2024, safety profile, efficacy, relapsed/refractory multiple myeloma

Gilead and Arcellx Highlight Promising CAR T Therapy for Multiple Myeloma with Enhanced Safety Profile

7 months ago talkbio0Tagged Arcellx, Automobiles, Clinical Trials, Effectiveness, Gilead, Multiple Myeloma, safety profile, T therapy

CAR T therapy, multiple myeloma, anito-cel, Gilead, Arcellx, safety profile, efficacy, clinical trials